Eur J Endocrinol. 2023;188(4):385-394.
In-depth proteomic signature of parathyroid carcinoma.
제1저자 공성혜, 이준협 · 교신저자 한도현, 김정희
소속 (12)
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
- Department of Surgery, Gachon University Gil Medical Center, Incheon, South Korea.
- Department of Pathology, Seoul National University Hospital, Seoul, South Korea.
- Department of Internal Medicine, Severance Hospital, Seoul, South Korea.
- Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea.
- Department of Endocrinology and Metabolism, College of Medicine, Kyung Hee University, Seoul, South Korea.
- Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea.
- Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, South Korea.
- Transdisciplinary Department of Medicine & Advanced Technology, Seoul National University Hospital, Seoul, South Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Abstract
OBJECTIVE Diagnosing parathyroid carcinoma (PC) is complicated and controversial that early diagnosis and intervention are often difficult. Therefore, we aimed to elucidate the protein signatures of PC through quantitative proteomic analyses to aid in the early and accurate diagnosis of PC.
DESIGN We conducted a retrospective cohort study.
METHODS We performed liquid chromatography with tandem mass spectrometry using formalin-fixed paraffin-embedded samples. For the analyses, 23 PC and 15 parathyroid adenoma (PA) tissues were collected from 6 tertiary hospitals in South Korea.
RESULTS The mean age of the patients was 52 years, and 63% were women. Proteomic expression profiling revealed 304 differentially expressed proteins (DEPs) with a cut-off of P < .05 and fold change >1.5. Among DEPs, we identified a set of 5 proteins that can discriminate PC from PA: carbonic anhydrase 4 (CA4), alpha/beta hydrolase domain-containing protein 14B (ABHD14B), laminin subunit beta-2 (LAMB2), CD44 antigen (CD44), and alpha-1-acid glycoprotein 1 (ORM1) that exhibited the highest area under the curve of 0.991 in neural network model. The nuclear percentage of CA4 and LAMB2 in immunohistochemistry was significantly lower in PC tissue than in the PA (CA4: 2.77 ± 1.96%, 26.2 ± 3.45%, P < .001; LAMB2: 6.86 ± 3.46%, 38.54 ± 4.13%, P < .001). The most enriched canonical pathways in PC included glycoprotein-6 signaling and mammalian target of rapamycin (mTOR).
CONCLUSIONS We identified key proteins differentially expressed between PC and PA using proteomic analyses of parathyroid neoplasms. These findings may help to diagnose PC accurately and elucidate potential therapeutic targets.
© The Author(s) 2023. Published by Oxford University Press on behalf of (ESE) European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Keywords
parathyroidparathyroid adenomaparathyroid carcinomaproteomics
Conflict of interest statement
Conflicts of interest: All authors have nothing to declare.
그 밖의 정보
- 출판 형태
- Journal Article
- 저널
- European journal of endocrinology · eISSN 1479-683X
- MeSH
- Humans · Female · Middle Aged · Male · Parathyroid Neoplasms* / metabolism · Retrospective Studies · Proteomics · Republic of Korea
- 연구비
- Korean Endocrine Society